Research programme: metabotropic glutamate receptor 4 modulators - Addex Therapeutics

Drug Profile

Research programme: metabotropic glutamate receptor 4 modulators - Addex Therapeutics

Alternative Names: ADX 88178; mGluR4 modulators - Addex Therapeutics; mGluR4 PAM; VU0003423

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Addex Pharmaceuticals; Merck & Co
  • Developer Addex Therapeutics; Ecole Polytechnique Federale de Lausanne.; University of Lausanne
  • Class Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 4 agonists; Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autistic disorder; Cocaine abuse
  • No development reported Anxiety disorders; Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in Switzerland (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Switzerland (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top